T cell receptor (TCR) ligand discovery is essential for understanding and manipulating immune responses to tumors. We developed a cell-based selection platform for TCR ligand discovery that exploits a membrane transfer phenomenon called trogocytosis. We discovered that T cell membrane proteins are transferred specifically to target cells that present cognate peptide-major histocompatibility complex (MHC) molecules. Co-incubation of T cells expressing an orphan TCR with target cells collectively presenting a library of peptide-MHCs led to specific labeling of cognate target cells, enabling isolation of these target cells and sequencing of the cognate TCR ligand. We validated this method for two clinically employed TCRs and further used the platform to identify the cognate neoepitope for a subject-derived neoantigen-specific TCR. Thus, target cell trogocytosis is a robust tool for TCR ligand discovery that will be useful for studying basic tumor immunology and identifying new targets for immunotherapy.
T cells mediate adaptive immunity through direct, antigen-specific contact with target cells. The antigenic specificity of each T cell is determined by its unique TCR 1 , which binds a cognate peptide ligand (epitope) presented on MHC protein molecules on the target cell surface. TCR ligand discovery is fundamental to characterizing adaptive immune responses to pathogens and tumors, as well as inappropriate responses to self-and dietary antigens 2, 3 . This knowledge also enables clinically beneficial immunotherapies (for example, TCR gene transfer and vaccines) that initiate, amplify or attenuate immune responses to target antigens 4, 5 . Peptide-MHC (pMHC) multimer technologies enable monitoring of T cell-mediated responses to a selected panel of antigens 6 , but require foreknowledge of those antigenic targets relevant to the response. Unbiased screens with pMHC multimers on the scale of peptide screens used for TCR ligand discovery are precluded because even modern innovations enable the construction of at most a few thousand pMHC reagents in parallel 7 . In the context of cancer, tumor neoantigens arising from tumorspecific mutations can be discovered through exome sequencing and then used to interrogate T cells using pMHC multimers or neoantigen-transduced antigen-presenting cells 8, 9 . However, this approach limits the characterization of antitumor immunity to private neoantigen-specific clones and cannot be generalized to other immune responses less focused on mutant epitopes (for example, pathogen-specific immunity and autoimmunity). An alternative to interrogating a T cell response with preselected antigens is to identify TCRs mediating that response and use those TCRs to interrogate an antigenic library. TCRs mediating an immune response of interest can be identified by sequencing of T cells that are phenotypically implicated in that response or that are enriched among clonal T cells at the site of that response [10] [11] [12] [13] [14] [15] [16] [17] . However, the antigenic specificities of these orphan TCRs are typically unknown, which limits understanding of antitumor immunity and the potential clinical applications of these TCRs. Thus, there remains a need for technologies that can rapidly and robustly identify ligands reactive to orphan TCRs of interest for both basic and translational research.
Trogocytosis is a biological phenomenon by which cells share membrane and membrane-associated proteins while conjugated 18 . Although trogocytosis is bidirectional between conjugated Fcγ R-expressing cells (for example, monocytes) and immunoglobulin-bound cells (for example, anti-CD20-bound B cells) 19 , it has been described as unidirectional for primary T cells conjugated to unengineered antigen-presenting cells. Specifically, T cells extract membrane and membrane-associated proteins from target antigen-presenting cells with which they are conjugated 18, [20] [21] [22] [23] . The reverse process has been reported only for T cells using antigen-presenting cells loaded with cognate peptides 24, 25 . In this study, we show that antigen-presenting target cells genetically engineered to present supraphysiological levels of epitope can extract membrane and membrane-associated proteins from interacting T cells. Moreover, antigen-specific target cell trogocytosis can be tracked by multiple-protein transfer and by loss of proteins from donor cells. We have developed a TCR ligand discovery platform that exploits this phenomenon to selectively mark target cells that present genetically encoded epitopes cognate to orphan TCR-transduced T cells, enabling their isolation from a target cell library.
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Results
Trogocytosis occurs from T cell to target cell . We first establi shed cell lines expressing cognate TCR-antigen pairs, including Jurkat cells expressing either F5-TCR or 1G4-TCR and K562 cells expressing their cognate single-chain trimer (SCT) of HLA-A2/ MART1 26-35(A27L) or A2/NYESO1 157-165(C165V) (Fig. 1a and Supplemen tary Fig. 1a ). To test whether T cell membrane is transferred to target cells upon antigen-specific interaction, we labeled T cell surface proteins with N-hydroxysuccinimido (NHS)-biotin and monitored their transfer to target cells during co-incubation. As we expected, low-affinity nerve growth factor receptor (LNGFR) + Jurkat T cells treated with NHS-biotin stained strongly with streptavidin ( Fig. 1b and Supplementary Fig. 1b) , whereas ZsGreen + K562 cells that were not co-incubated with biotinylated Jurkat cells were negative for streptavidin ( Fig. 1c and Supplementary Fig. 1b ). Co-incubation of biotinylated F5-Jurkat cells with noncognate NYESO1-K562 cells led to a > 30-fold shift in streptavidin staining, which is indicative of nonspecific biotin transfer to target cells. However, the co-incubation of biotinylated F5-Jurkat cells with cognate MART1-K562 cells led to a further 3.5-fold shift over this nonspecific shift, demonstrating antigen-specific target cell trogocytosis (Fig. 1c) . Notably, both LNGFR and TCR, but not intracellular protein Zsgreen, exhibited a similar two-to threefold shift when MART1-K562 cells were co-incubated with F5-Jurkat cells, without any nonspecific shift for NYESO1-K562 cells ( Fig. 1d and Supplementary Fig. 2a ). We repeated this experiment without biotinylating the Jurkat T cells, using antibodies alone to monitor the transfer of T cell proteins to target cells upon co-incubation for different periods of time ( Fig. 1e and Supplementary Fig. 2b,c) . With 30 min of co-incuba tion, NYESO1-K562 and MART1-K562 cells extracted LNGFR and TCR from Jurkat T cells expressing their respective cognate TCRs but not from those expressing the noncognate TCR. Immunofluorescence staining with pMHC dextramers further confirmed the antigenic specificity of target cell trogocytosis ( Supplementary Fig. 2d ). In addition to LNGFR and TCR, CD3 and CD8 proteins were transferred from Jurkat cells to K562 cells, and HLA-A2 was transferred from K562 cells to Jurkat cells in an antigen-dependent manner ( Supplementary Fig. 3a,b) . Moreover, we observed an accompanying antigen-dependent reduction of proteins from donor cells, including HLA-A2 from K562 cells and TCR and LNGFR from Jurkat cells ( Supplementary Fig. 3c,d ). Thus, trogocytosis is bidirectional and mass balance is observed. In addition to F5-and 1G4-TCR, we also observed antigen-specific target cell trogocytosis for each of eight additional TCR-pMHC cognate pairings, including a low-affinity A2-restricted MART1-specific TCR 26 , four novel A2-restricted NY-ESO-1-specific TCRs of varying affinity and three NY-ESO-1-specific TCRs restricted on various MHC alleles (HLA-B*0702, B*18:01 and C*03:04) 27 ( Supplementary Fig. 4 ).
Trogocytosis scales with pMHC density and is enhanced by CD8. To determine whether trogocytosis intrinsically depends on the identities of donor and acceptor cells, we generated K562 cell lines and Jurkat cell lines expressing either TCR or SCT and performed co-incubation experiments using all pairing combinations. We observed antigen-specific TCR transfer for all cell pairings ( Supplementary Fig. 5 ), indicating that target cell trogocytosis does not depend on the identities of donor and acceptor cells. Target cell trogocytosis has been reported in experiments using supraphysiological levels of pulsed peptide 24, 25 . Our observation of target cell trogocytosis may therefore be explained by the supraphysiological expression of SCTs on the target cell surface. To test whether trogocytosis scales with increasing pMHC density, we pulsed K562 cells expressing HLA-A2 (A2-K562) with either MART1 heteroclitic peptide (ELAGIGILTV) or NYESO1 heteroclitic peptide (SLLMWITQV) at various concentrations and performed coculture experiments. Target cells pulsed with MART1 peptide exhibited a peptide-concentration-dependent increase in TCR transfer from cognate F5-Jurkat cells (but not from noncognate 1G4-Jurkat cells) (Fig. 2a , top, and Supplementary  Fig. 6a ). Similarly, target cells pulsed with NYESO1 peptide exhibited increased trogocytosis with increasing peptide concentration only when co-incubated with cognate 1G4-Jurkat cells (Fig. 2a , bottom, and Supplementary Fig. 6b ). Thus, target cell trogocytosis is antigen specific and its magnitude depends on the density of pMHC.
F5-TCR-expressing T cells respond to different MART1 peptide variants to different extents 28 . For example, F5-TCR is more responsive to the heteroclitic MART1 peptide (ELAGIGILTV) than to the native MART1 peptide (EAAGIGILTV). We examined the extent to which different MART1 peptide variants elicit trogocytosis by incubating F5-Jurkat or 1G4-Jurkat cells with A2-K562 cells that were pulsed with different MART1 peptide variants at the same dose. We found that there were more trogocytosis + target cells in the mixture of F5-Jurkat and ELAGIGILTV peptide-pulsed A2-K562 cells than in F5-Jurkat and A2-K562 cells pulsed with native EAAGIGILTV peptide or other peptide variants (Fig. 2b , top, and Supplementary  Fig. 6c ). Similarly, there was more TCR transfer to A2-K562 cells pulsed with heteroclitic NYESO1 peptide than to those pulsed with native peptide or other peptide variants (Fig. 2b , bottom, and Supplementary Fig. 6d ).
Coexpression of CD8 increases the avidity of the TCR-pMHC interaction by binding to MHC I directly, enabling lower-affinity TCRs to engage 29 . We found that Jurkat cells coexpressing CD8 mediated significantly enhanced trogocytosis relative to those expressing only TCR for each of three TCRs tested, including the low-affinity M1W-TCR ( Fig. 2c and Supplementary Fig. 7 ). Thus, our results suggest that target cell trogocytosis depends on the density of the presented epitope and that it is enhanced when donor cells coexpress CD8.
Trogocytosis enables isolation of cognate target cells. In addition to providing the supraphysiological levels of pMHC presentation necessary for target cell trogocytosis, SCTs genetically encode the epitope presented. We devised an epitope discovery strategy in which donor cells expressing an orphan TCR label target cells presenting their cognate epitope via trogocytosis, facilitating isolation of these target cells from a library by fluorescence-activated cell sorting (FACS) and epitope identification by next-generation sequencing (NGS). To determine whether target cell trogocytosis enables separation of cognate epitope-presenting target cells from noncognate epitope-presenting cells, we co-incubated either 1G4-Jurkat or F5-Jurkat T cells with a 1:1 mixture of NYESO1-K562 and MART1-K562 target cells and then labeled the cell mixture with soluble 1G4-or F5-TCR multimers. This allowed us to determine the antigenic composition of target cells undergoing trogocytosis ( Supplementary Fig. 8a ). When a mixture of NYESO1-K562 and MART1-K562 target cells was co-incubated with 1G4-Jurkat cells, trogocytosis + target cells were highly enriched (95.5%) for cognate NYESO1-K562 cells ( Supplementary Fig. 8b,c) . Similarly, coincubation of the target cell mixture with F5-Jurkat cells enriched MART1-K562 (94.6%) among trogocytosis + target cells. Thus, target cell trogocytosis is itself antigen specific and enables resolution of antigen-expressing target cells from non-antigen-expressing cells.
To determine whether detection of target cell trogocytosis is sufficiently sensitive for the identification of a cognate TCR ligand from a library of noncognate ligands, we conducted a proof-of-concept library simulation. We diluted ZsGreen + NYESO1-K562 cells 1:10,000 into CD80 
CD80
+ HLA-A2 + K562 cells after co-incubation with either Jurkat cell type. The experiment was repeated using one MART1-K562 cell per 10,000 control cells, yielding a similar result (Fig. 3b) . Thus, Anti-TCRab-PE-Cy7
Anti-TCRab-PE-Cy7 Articles NaTuRe MeTHods target cell trogocytosis can be used to detect cognate antigenexpressing target cells at a ratio at least as low as 1:10,000.
Having determined the sensitivity with which target cell trogocytosis resolves cognate target cells from those presenting a noncognate ligand, we next determined the specificity with which trogocytosis separates cognate target cells from cells presenting a more extensive library of ligands. We generated an A2-restricted SCT cDNA library containing 12,055 public T cell epitopes from the Immune Epitope Database ranging from 8-12 amino acids in length, including the epitopes specific to the F5-and 1G4-TCRs. We then transduced K562 cells with the A2-restricted SCT library, co-incubated the transduced target cell library with F5-Jurkat or 1G4-Jurkat cells, and separated trogocytosis + target K562 cells by FACS (Fig. 4a and Supplementary Fig. 9a,b) . After two rounds of trogocytosis selection, the specificity of sorted K562 cells was validated by trogocytosis experiments (Fig. 4b) . Furthermore, target K562 cells sorted after co-incubation with F5-Jurkat cells were 95% positive for F5-TCR dextramer staining (increased from 37% after one round of sorting) (Fig. 4c, top) and target K562 cells sorted after co-incubation with 1G4-Jurkat cells were 86% positive for 1G4-TCR dextramer staining (increased from 25% after one round of sorting) (Fig. 4c, bottom) . In contrast, sorted cells were negative for dextramer staining in noncognate pairings for both rounds of sorting (Fig. 4c) . Target cells from the second round of each trogocytosis selection were subjected to NGS to identify the enriched epitopes. Eight of the top nine enriched ligands from the F5-Jurkat selection were the cognate native and heteroclitic ligands (EAAGIGILTV and ELAGIGILTV) for F5-TCR or closely related ligands. The top two ligands from the 1G4-Jurkat selection were likewise the cognate native and heteroclitic ligands (SLLMWITQC and SLLMWITQV) for 1G4-TCR (Fig. 4d ). These data demonstrate that target cell trogocytosis provides a platform for identifying cognate ligands and cross-reactive ligands of similar sequence for orphan TCRs.
Trogocytosis identifies the ligand of a subject-derived neoTCR.
Recent advances in genomics and proteomics, along with supportive bioinformatics and in silico prediction tools, have enabled the rapid identification of mutated neoepitopes from subject-derived tumors 30, 31 . We next determined whether this platform can identify the cognate neoepitope for a tumor-infiltrating lymphocyte-derived orphan TCR from a custom library of privately mutated, subjectspecific neoepitopes. We identified private mutations by exome and RNA sequencing of tumor material from a subject with metastatic melanoma, predicted which of these mutations generated neoepit 
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NaTuRe MeTHods target cells (Supplementary Fig. 9c ). The top five ligands enriched after two rounds of selection were overlapping mutated peptides derived from ubiquitin-specific peptidase 7 (USP7) (Fig. 5a ). To verify that the neo-TCR recognizes the enriched neoepitopes, K562 cells were transduced with an SCT encoding the core nonamer mutant peptide YLYHRVDVI (mutUSP7-K562) contained in all enriched hits. As we expected, we observed significantly more trogocytosis + target cells after coincubation of mutUSP7-K562 with neo-TCR-Jurkat cells than with noncognate F5-Jurkat cells (Fig. 5b) , confirming that this USP7 mutant epitope is recognized by the neo-TCR. This was further validated by measuring the ability of the neo-TCR to induce cytotoxicity upon recognition of mutUSP7-K562 target cells (Fig. 5c) . Notably, mutUSP7 is a mutation that affects MHC binding rather than TCR recognition 31 . We found that both wild-type USP7-K562 and mutUSP7-K562 target cells exhibited target cell trogocytosis when co-incubated with neo-TCR T cells (Supplementary Fig. 10 ). This is probably because the employed disulfide-trapped SCT architecture enables presentation of the weak-binding wild-type peptide 32 , leading to TCR recognition despite the poor natural affinity of this peptide for the HLA-A2 binding groove. Articles NaTuRe MeTHods
Discussion
Our key discovery is that target cells presenting supraphysiological levels of a peptide epitope extract membrane-associated proteins from interacting T cells in an antigen-specific and pMHC-densitydependent manner. We have exploited this phenomenon to mark ligand-presenting target cells with extracted TCRs (and other membrane proteins) from cognate T cells, enabling ligand discovery, and we have validated this method using both public and neoepitope-specific TCRs. In a companion study 33 , we described the use of signaling and antigen-presenting bifunctional receptors in a second cell-based platform for TCR ligand discovery. These platforms exploit distinct biological mechanisms for the purpose of TCR ligand discovery, and the results obtained in our studies crossvalidate each other.
The trogocytosis-based platform has several key advantages over existing technologies for de novo TCR ligand discovery. In contrast to pMHC yeast display 34 , our method does not require producing orphan TCR protein reagents, but rather uses orphan TCRs expressed in their natural context. Similarly, whereas multimerbased approaches rely on purified pMHC protein reagents that are expensive and time-consuming to generate, we genetically encode the peptide ligand and MHC, enabling rapid, modular assembly of pMHC libraries presented on mammalian cells. We recently described an unbiased TCR-ligand discovery method using fluorescently labeled reagents derived from orphan TCR ectodomains to screen a yeast cell-surface-displayed pMHC library 34 . However, this method requires the production of soluble TCR ectodomains, which is laborious, nonrobust and low throughput. Furthermore, Articles NaTuRe MeTHods neither yeast display nor multimer libraries can be applied to additional MHC alleles without extensive development of allele-specific reagents (that is, optimization of each human MHC allele library on yeast cells or design and synthesis of exchange ligands unique to each MHC allele for multimer library production). Because membrane receptor recognition is interrogated in the cell-to-cell context, our trogocytosis-based platform can be readily extended to additional TCRs or MHC alleles in high throughput and without further optimization. This is key for clinical applications, as the MHC I locus is the most polymorphic in the human genome, and MHC haplotypes vary widely across individuals and between ethnic groups 35 . A similar level of trogocytosis was observed with A2-restricted TCRs of varying affinity for the same epitope, which suggests that individual TCR-pMHC affinity is not a critical parameter. The extent of trogocytosis could be augmented through coexpression of CD8 on the donor cells, presumably by increasing the avidity between T cells and cognate target cells. Thus, the trogocytosis-based cell platform is a robust tool for discovering ligands for orphan TCRs of various, unknown affinities, such as CD8-dependent TCRs (which would be poor candidates for antigen discovery via yeast display). We found that target cells presenting cognate pMHC could be identified by the transfer of any of multiple proteins that were involved in the T cell synapse (TCR, CD3 and CD8) or that were not (LNGFR∆ ). The ability to identify cognate TCR-pMHC interactions using multiple independent, commercially available reagents (antibodies) is yet another key advantage of trogocytosis over pMHC multimers or display technologies, for which TCR-pMHC binding is the sole selective axis. Unlike yeast display, in which bioinformatics is required to infer true biological ligands from the sequences of top synthetic ligand hits 34 , the top epitopes identified in our experiments are reliably the biological target ligands for the TCR being tested.
Although we have validated our method only using MHC I-restricted TCRs, it is amenable to application to MHC II-restricted responses. Such responses are central to autoimmune disease, and are emerging as important components of cancer immunotherapy 36, 37 . A similar platform could be conceived for other immunoreceptors (for example, chimeric antigen receptors and antibodies) using target cells expressing a library of suitable surface target proteins. Finally, this method can be used to determine whether a therapeutic candidate TCR of known specificity cross-reacts with self epitopes, thereby reducing the risk of serious adverse events 38 .
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Anti-muTCR-PECy7 DNA constructs. A murine-stem-cell-virus-based retroviral vector encoding F5-TCR, 1G4-TCR or neo-TCR genes carrying either human or murine TCR constant regions had the format TCRα -F2A-TCRβ -P2A-LNGFRΔ . LNGFRΔ is a transduction marker comprising low-affinity nerve growth factor receptor with the intracellular domain truncated. A lentiviral vector encoding ZsGreen/eGFP and peptide-MHC SCT composed of antigenic peptide (NY-ESO-1, SLLMWITQV; MART1, ELAGIGILTV; wild-type USP7, DLYHRVDVI; mutant USP7, YLYHRVDVI), β 2-microglobulin, and HLA-A2 domains via flexible glycine-serine linkers was prepared with a disulfide trap modification as described 40 . E2-Crimson and a CD3 fusion gene encoding CD3δ , CD3ε , CD3γ and CD3ξ were subcloned into a lentiviral vector. CD8 was subcloned into a retroviral vector. T cell activation and transduction. T cells were stimulated, transduced and cultured as described 40 . To transduce primary human T cells, peripheral blood mononuclear cells (2 × 10 6 cells ml -1 ) were activated in 24-well plates coated with 1 μ g ml -1 antibody to CD3 (clone OKT3, eBioscience) in the presence of 1 μ g ml -1 soluble antibody to CD28 (clone CD28.2, eBioscience) and 300 U ml -1 interleukin-2 (IL-2; Fisher Scientific) in T cell medium (AIM-V medium supplemented with 5% (v/v) human AB serum and antibiotics (penicillin-streptomycin)). After 48 h of activation, the cells were spin-infected with viral supernatant supplemented with 10 µ g ml -1 Polybrene for 90 min at 2,500 r.p.m. at 30 °C. After spin-infection, the retroviral supernatant was replaced with fresh T cell medium containing 300 U ml -1 IL-2 and 1 µ g ml -1 anti-CD28. The transduced primary T cells were cultured for 48 h and then used for cytotoxicity assays.
Surface biotin labeling. F5-Jurkat cells were resuspended at 10 million cells per ml in freshly prepared biotin solution (1 mg ml -1 in sterile PBS) and incubated for 10 min at room temperature. The cells were quenched with one equivalent of FBS and incubated for 10 min at 4 °C, then washed three times with 10 ml RPMI 1640 medium supplemented with FBS. The labeled cells were then used for co-incubation experiments.
Peptide loading of A2-K562 cells. Lyophilized peptides (Thermo Fisher) were reconstituted in dimethylsulfoxide to 10 mM and then further diluted in water to a 2 mM working stock. Five-fold serial dilutions of the peptides were performed using a 50 µ M starting solution (5 µ l of 2 mM working stock in 195 µ l of serumfree medium) until 80 nM was reached. Target A2-K562 cells (50,000 total, 0.5 × 10 6 cells ml -1
) were pulsed with 25 µ l of 5× serial peptide dilution in a 96-well U-bottom plate and incubated for 2 h at 37 °C. After incubation, 100 µ l of medium was added to each well and then centrifuged for 5 min at 1,500 r.p.m. The cell pellets were washed once with 200 µ l of medium and then resuspended in 100 µ l of medium for co-incubation experiments.
Co-incubation assay and cell staining and sorting. For experiments using F5-Jurkat, 1G4-Jurkat, MART1-K562 and NYESO-K562 cells, co-incubations were set up in 96-well U-bottom plates at a ratio of 5:1 Jurkat to K562 (300,000 cells per well) and co-incubated for 45 min at 37 °C. Ratios for co-incubation experiments involving SCT-Jurkat cells and TCR-K562 cells are indicated in the text and figure legends. The co-incubation was then centrifuged for 5 min at 1,500 r.p.m. and the medium was aspirated by vacuum. The cell pellets were resuspended with cold PBS solution containing 2 mM EDTA and then centrifuged. Cells were stained with different antibodies at 4 °C for 20 min, washed twice, and then analyzed by flow cytometry using MACSQuant Analyzer 10 (Miltenyi Biotec). The following antibodies were used to detect expression of surface markers: anti-CD3-PE, anti-CD8-BV510, anti-TCRα β -PacificBlue, anti-TCRα β -PE/Cy7, anti-LNGFR-PE, anti-LNGFR-APC, anti-HLA-A2-PacificBlue, anti-HLA-A2-BV510, and anti-muTCRα β -PE/Cy7 (all from Biolegend). Flow cytometry gating strategies are described in the Supplementary Note. Dextramer binding on SCT-K562 cells. We prepared F5-TCR or 1G4-TCR dextramers by using fluorescently labeled streptavidin (Life Technologies) as described 26 . SCT-transduced K562 cells were stained with TCR dextramer and 7AAD (eBioscience) for 20 min at room temperature. Stained cells were analyzed by flow cytometry using MACSQuant Analyzer 10 (Miltenyi Biotec).
Co-incubation experiments
Immunofluorescence staining. Co-incubated cells were stained with MART1 pMHC dextramer (ELAGIGILTV) conjugated to PE and then treated with 4% formaldehyde, followed by incubation at room temperature for 10 min. Cells were washed three times with PBST (PBS plus 0.1% Triton X-100) for 5 min and then placed on the slide with mounting medium. Images were acquired on Zeiss LSM880.
Cytotoxicity assays with primary human T cells using calcein AM. To measure the cytotoxic response of effector T cells to target cells, we carried out a calcein AM release-based cytotoxicity assay as described 41 . Briefly, 1 × 10 6 SCT-K562 target cells were resuspended in 1 ml of calcein AM (Thermo Fisher) in cell medium (5 µ l ml -1 ), incubated for 1 h at 37 °C while being shaken occasionally, and then washed twice with cell medium to remove residual dye. Effector T cells transduced with F5-TCR or neo-TCR and target SCT cells were plated on a 96-well U-bottom plate in various effector-to-target ratios (16:1, 8:1, 4:1, 2:1, 1:1, 0.5:1 and 0:1) and co-incubated for 4 h at 37 °C. After co-incubation, cell-free supernatant was carefully removed and analyzed using a fluorescence plate reader (excitation filter, 485 nm; emission filter, 530 nm). The percentage of specific lysis was calculated using the formula [(test release -spontaneous release)/(maximum releasespontaneous release)] × 100 based on the optical density measured. Target cells in the spontaneous release well were incubated with medium alone (considered as 0% lysis), and target cells in the maximum release well were incubated with 2% Triton X-100 (considered as 100% lysis).
Library generation. The A2-restricted SCT cDNA library contains ~12,055 public T cell epitopes from the Immune Epitope Database (https://www.iedb.org/). The neoantigen SCT cDNA library contains ~3,000 unique neoantigens that had been identified independently by exome and RNA sequencing of tumor material from a melanoma subject and predicting neoantigen presentation by HLA-A*02:01 (data not shown). The oligonucleotide pool encoding A2-restricted public and neoantigen neoepitopes was synthesized (Twist Bioscience) and used as the template for PCR amplification using primers 5′ -CAGGAGGGCTCGGCA-3′ and 5′ -GATGAGCGGCCGCCGGACCCTCCGCATCC-3′ with the following program: initial denaturation step at 95 °C for 2 min followed by six cycles of 95 °C for 20 s, 61 °C for 10 s, and 70 °C for 15 s, then a final extension at 70 °C for 1 min, followed by a 4 °C hold. After PCR amplification of the oligonucleotide library, the PCR amplicons were digested with NotI and then inserted into a BsmBI-digested lentiviral vector with internal-ribosome-entry-site-mediated coexpression of a GFP gene by In-Fusion cloning. The lists of epitopes in the A2-restricted SCT cDNA library and the neoantigen SCT cDNA library are in Supplementary Tables 1 and 2. PCR amplification and deep sequencing. Genomic DNA of sorted SCT-K562 cells was extracted using the PureLink Genomic DNA Mini Kit (Invitrogen) and used as template in barcoded PCR amplification in a Mastercycler Pro S PCR System (Eppendorf) with the following program: initial denaturation step at 95 °C for 2 min followed by 35 
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